Streetbeat News

BVXV

Biondvax Pharmaceuticals Ltd

http://www.biondvax.com

CEO

Ron Babecoff

Employees

Industry

Biological Product (except Diagnostic) Manufacturing

biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. biondvax’s technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.

Open

1.32

Mkt cap

Volume

23K

High

1.36

P/E Ratio

-0.58

52-wk high

11.49

Low

1.31

Div yield

N/A

52-wk low

0.63

BiondVax Pharmaceuticals reported Q2 earnings per share (EPS) of $(0.003), a significant improvement from $(2.00) YoY. This represents a 99.85% increase in earnings.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 1:02 pm

Nasdaq has granted BiondVax Pharmaceuticals an extension to regain compliance with listing rules. The company now has until February 2023 to meet the minimum $1.00 bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:30 am

On Tuesday, 32 companies reached new 52-week lows, with Vodafone Group being the largest in terms of market cap and Nova Lifestyle being the smallest. OceanPal's stock had the biggest downward move, diving 26.32%, while EBET shares bounced back the most, rising 0.0% after hitting a new low.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 5:44 pm

On Tuesday, 69 stocks hit new 52-week lows, with Estee Lauder being the largest company by market cap to set a new low. Westport Fuel Systems shares dropped the most, while Greenidge Generation Hldg shares rebounded the highest.

Portfolio Pulse from Benzinga Insights

June 06, 2023 | 5:54 pm

Amedisys shares surged 14.2% after receiving an unsolicited proposal from Optum for $100 per share. Other stocks with significant gains include Sono Group, Forza X1, Chijet Motor Company, and CIRCOR International. Bellerophon Therapeutics and Castle Biosciences were among the biggest losers.

Portfolio Pulse from Lisa Levin

June 05, 2023 | 5:09 pm

12 health care stocks experienced significant price movements during Monday's pre-market session, with Timber Pharmaceuticals, Evaxion Biotech, and BiondVax Pharmaceuticals among the gainers, while Bellerophon Therapeutics, Mallinckrodt, and Cibus were among the losers.

Portfolio Pulse from Benzinga Insights

June 05, 2023 | 1:06 pm

BiondVax Pharmaceuticals has signed a worldwide license agreement to develop an antibody for the treatment of autoimmune and inflammatory diseases, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:45 pm

BiondVax has signed an exclusive worldwide license agreement to develop and commercialize a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, including psoriasis.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 11:11 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.